Any current/future new fundraising through debt or equity?

No mention of any new fundraising through equity in the provided transcript. Current debt as of September 30, 2016, stands at Rs. 243 crores (including Rs. 27 crores promoter funding). The company has repaid Rs. 12 crores term loan in H1 FY17 and expects to reduce outside debt by a similar amount in H2 FY17. A line of credit sanction from banks is in final approval phase, expected to be released within 1 to 1.5 months to meet working capital needs. Promoters have extended Rs. 27 crores loan at a lower interest rate to replace higher-cost NBFC funding, which will help reduce interest co

Any current/future capex/capital investment/strategic investment?

Current CAPEX mainly for debottlenecking, replacing old equipment, and upgrading API manufacturing facilities to WHO GMP standards (Page 11). Unit 5, a new manufacturing unit for veterinary APIs, is under construction with expected commissioning by Q4 FY17; initial capacity utilization starts at 30-40%, ramping up to 80% by FY19 (Pages 8-10). Post-commissioning of Unit 5 and ongoing CAPEX, the company expects doubling of turnover by mid-FY20 (Page 9). CAPEX related to upgrading other facilities (LASA, Urdhwa) to support regulatory market supply and higher margins (Page 11). No major new CAPEX

Future growth expectations in earnings/operating earnings/profits/EPS?

Company expects revenue to potentially double by mid-FY20 with full capacity utilization of new Unit 5. Growth rate projected conservatively at 15%-20% annually for both parent company and LASA Super Generics. EBITDA margin improvements noted with 20% margin in H1 FY17; continuing focus on operating efficiencies and productivity. PAT grew by 31% YoY in H1 FY17, indicating improving profitability. New molecule launches and scale-up of existing products are main growth drivers. Expansion of exports mainly to European regulatory markets expected to continue. CAPEX largely completed, mainly for de

Current/ Expected Orderbook/ Pending Orders?

The management expects strong order flow driven by new molecule launches and scale-up of existing products. Orders are primarily from regulatory markets, especially Europe (Germany, France, Spain, Belgium). Current capacity utilization for existing units is high (75%-87%), with Unit 5 expected to commence production in Q4 FY17. Unit 5 will gradually ramp up to full capacity by FY19, potentially doubling turnover by mid-FY20. Growth momentum continues in Q3 FY17 with stable export orders; Q4 expected to see fewer orders due to holidays but with new orders anticipated from January. Orderbook out

IN US

Sale is live|00:00:00left today

Omkar Speciality Chemicals LtdQ3 FY16Chemicals & Petrochemicals

Omkar Speciality Chemicals Ltd Q3 FY16 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3.41Market Cap: ₹7 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

- Expect turnover to double by mid-FY20 due to full capacity utilization of new unit 5. - Capacity utilization for new unit 5 will ramp up gradually: 30-40% initially, 55-60% next, then 70-75%, reaching 80% by FY19. - Planned growth rate for both parent company and LASA super generics is 15%-20% annually. - Growth driven by: * Launch of new molecules with customer approvals. * Scale-up of existing products. - Export growth momentum sustained, with ongoing focus on European markets (Germany, France, Spain, Belgium). - Business segments (API and specialty chemicals) expected to maintain steady contributions, with APIs growing to 15%-20% of revenue. - Order flow expected to support expansion without issues. - Overall, conservative estimates indicate steady growth aligned with capacity expansions and market demand.

Margin guidance

Category 3

→Company expects revenue to potentially double by mid-FY20 with full capacity utilization of new Unit 5.
→Growth rate projected conservatively at 15%-20% annually for both parent company and LASA Super Generics.
→EBITDA margin improvements noted with 20% margin in H1 FY17; continuing focus on operating efficiencies and productivity.
→PAT grew by 31% YoY in H1 FY17, indicating improving profitability.
→New molecule launches and scale-up of existing products are main growth drivers.
→Expansion of exports mainly to European regulatory markets expected to continue.
→CAPEX largely completed, mainly for debottlenecking and facility upgrades to WHO GMP standards, supporting growth.
→Demerger and depledging processes expected to unlock shareholder value and improve financial flexibility.
→No major capex expected beyond current projects, implying stable margins.
→Overall strong growth momentum and controlled working capital indicating sustainable profit growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→No mention of any new fundraising through equity in the provided transcript.
→Current debt as of September 30, 2016, stands at Rs. 243 crores (including Rs. 27 crores promoter funding).
→The company has repaid Rs. 12 crores term loan in H1 FY17 and expects to reduce outside debt by a similar amount in H2 FY17.
→A line of credit sanction from banks is in final approval phase, expected to be released within 1 to 1.5 months to meet working capital needs.
→Promoters have extended Rs. 27 crores loan at a lower interest rate to replace higher-cost NBFC funding, which will help reduce interest cost.
→No explicit statement regarding fresh fundraising through debt or equity; focus is on optimizing existing credit lines and replacing high-cost funds.

Order book

Yes

→The management expects strong order flow driven by new molecule launches and scale-up of existing products.
→Orders are primarily from regulatory markets, especially Europe (Germany, France, Spain, Belgium).
→Current capacity utilization for existing units is high (75%-87%), with Unit 5 expected to commence production in Q4 FY17.
→Unit 5 will gradually ramp up to full capacity by FY19, potentially doubling turnover by mid-FY20.
→Growth momentum continues in Q3 FY17 with stable export orders; Q4 expected to see fewer orders due to holidays but with new orders anticipated from January.
→Orderbook outlook is positive and the company does not foresee issues in meeting order demand with enhanced capacity.
→The company’s export orders are mostly billed in US dollars (~90%) with some in euros.

Capex plans

Yes

→Current CAPEX mainly for debottlenecking, replacing old equipment, and upgrading API manufacturing facilities to WHO GMP standards (Page 11).
→Unit 5, a new manufacturing unit for veterinary APIs, is under construction with expected commissioning by Q4 FY17; initial capacity utilization starts at 30-40%, ramping up to 80% by FY19 (Pages 8-10).
→Post-commissioning of Unit 5 and ongoing CAPEX, the company expects doubling of turnover by mid-FY20 (Page 9).
→CAPEX related to upgrading other facilities (LASA, Urdhwa) to support regulatory market supply and higher margins (Page 11).
→No major new CAPEX expected beyond current projects in the next 2-3 years; focus is on expansion and utilization of existing/upgraded capacities (Page 11).
→Total WIP as of September 2016 is ₹140 crores, primarily related to Unit 5 and API upgrades; expected capitalization by March 2017 if commissioning completes on time (Page 11).

How does Omkar Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Omkar Speciality Chemicals Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Omkar Speciality Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio